Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.

Zinner NR, Bidair M, Centeno A, Tomera K

Urology1 Dec 2004Cited by 40 (Europe PMC)

PMID15596193DOI10.1016/j.urology.2004.07.033PepBankPUB-15596193

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with prostate cancer, type 3 surges occurred in 34 (27.0%) with goserelin 3.6 mg versus 20 (17.7%) with 10.8 mg (P = 0.065).
In plain wordsIn men with prostate cancer, type 3 surges did not differ significantly between goserelin doses.
Peptide
Goserelin
Outcome
No significant changeType 3 testosterone surge frequency
Study
n: not reported in source
Comparator
Goserelin 10.8 mg every 84 days
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.6 mg every 28 days · 48 weeksAs given in this study (human).
Measurements
Patients with type 3 surge
34 patients
3.6 mg
Type 3 surge rate
27%
3.6 mg
Patients with type 3 surge
20 patients
10.8 mg
Type 3 surge rate
17.7%
10.8 mg
Source sentences
Summary
Type 3 surges occurred after one or more repeat injections in 34 (27.0%) and 20 (17.7%) patients in the 3.6-mg and 10.8-mg groups, respectively (P = 0.065); the mean surge (+/- standard deviation) was 11.2 ng/dL (+/-13.5) and 17.3 ng/dL (+/-24.6), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Men with prostate cancer for whom hormonal therapy was indicated were randomized to open-label goserelin 3.6 mg every 28 days (n = 129) or 10.8 mg every 84 days (n = 118) for 48 weeks.
Report a problemFND-1559619303
02HumanNon-randomized trialEfficacy outcome
In men with prostate cancer given goserelin 3.6 mg, the mean surge reported with type 3 surges was 11.2 ng/dL with standard deviation 13.5.
In plain wordsIn men with prostate cancer given goserelin 3.6 mg, the mean surge reported with type 3 surges was 11.2 ng/dL.
Peptide
Goserelin
Outcome
IncreaseMean testosterone surge magnitude
Study
n = 34
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.6 mg every 28 days · 48 weeksAs given in this study (human).
Measurements
Mean surge
11.2 ng/dL
3.6 mg
Surge standard deviation
13.5 ng/dL
3.6 mg
Source sentences
Summary
Type 3 surges occurred after one or more repeat injections in 34 (27.0%) and 20 (17.7%) patients in the 3.6-mg and 10.8-mg groups, respectively (P = 0.065); the mean surge (+/- standard deviation) was 11.2 ng/dL (+/-13.5) and 17.3 ng/dL (+/-24.6), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Men with prostate cancer for whom hormonal therapy was indicated were randomized to open-label goserelin 3.6 mg every 28 days (n = 129) or 10.8 mg every 84 days (n = 118) for 48 weeks.
Report a problemFND-1559619304
03HumanNon-randomized trialEfficacy outcome
In men with prostate cancer given goserelin 10.8 mg, the mean surge reported with type 3 surges was 17.3 ng/dL with standard deviation 24.6.
In plain wordsIn men with prostate cancer given goserelin 10.8 mg, the mean surge reported with type 3 surges was 17.3 ng/dL.
Peptide
Goserelin
Outcome
IncreaseMean testosterone surge magnitude
Study
n = 20
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
10.8 mg every 84 days · 48 weeksAs given in this study (human).
Measurements
Mean surge
17.3 ng/dL
10.8 mg
Surge standard deviation
24.6 ng/dL
10.8 mg
Source sentences
Summary
Type 3 surges occurred after one or more repeat injections in 34 (27.0%) and 20 (17.7%) patients in the 3.6-mg and 10.8-mg groups, respectively (P = 0.065); the mean surge (+/- standard deviation) was 11.2 ng/dL (+/-13.5) and 17.3 ng/dL (+/-24.6), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Men with prostate cancer for whom hormonal therapy was indicated were randomized to open-label goserelin 3.6 mg every 28 days (n = 129) or 10.8 mg every 84 days (n = 118) for 48 weeks.
Report a problemFND-1559619305
04HumanNon-randomized trialEfficacy outcome
In men with prostate cancer receiving goserelin 10.8 mg, two patients (1.8%) had a type 1 surge after one repeat injection.
In plain wordsIn men with prostate cancer given goserelin 10.8 mg, two patients (1.8%) had a type 1 testosterone surge.
Peptide
Goserelin
Outcome
Not applicableType 1 testosterone surge
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
10.8 mg every 84 days · 48 weeksAs given in this study (human).
Measurements
Patients with type 1 surge
2 patients
10.8 mg
Type 1 surge rate
1.8%
10.8 mg
Source sentences
Summary
Two patients (1.8%) in the 10.8-mg group had a type 1 surge after one repeat injection and two (1.6%) in the 3.6-mg group had a type 2 surge after one repeat injection.
1 context sentence(design, population, supporting numbers)
Summary · context
Men with prostate cancer for whom hormonal therapy was indicated were randomized to open-label goserelin 3.6 mg every 28 days (n = 129) or 10.8 mg every 84 days (n = 118) for 48 weeks.
Report a problemFND-1559619301
05HumanNon-randomized trialEfficacy outcome
In men with prostate cancer receiving goserelin 3.6 mg, two patients (1.6%) had a type 2 surge after one repeat injection.
In plain wordsIn men with prostate cancer given goserelin 3.6 mg, two patients (1.6%) had a type 2 testosterone surge.
Peptide
Goserelin
Outcome
Not applicableType 2 testosterone surge
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.6 mg every 28 days · 48 weeksAs given in this study (human).
Measurements
Patients with type 2 surge
2 patients
3.6 mg
Type 2 surge rate
1.6%
3.6 mg
Source sentences
Summary
Two patients (1.8%) in the 10.8-mg group had a type 1 surge after one repeat injection and two (1.6%) in the 3.6-mg group had a type 2 surge after one repeat injection.
1 context sentence(design, population, supporting numbers)
Summary · context
Men with prostate cancer for whom hormonal therapy was indicated were randomized to open-label goserelin 3.6 mg every 28 days (n = 129) or 10.8 mg every 84 days (n = 118) for 48 weeks.
Report a problemFND-1559619302
06HumanNon-randomized trialSafety outcome
In men with prostate cancer receiving goserelin, no patient with a testosterone surge had clinical symptoms of tumor flare.
In plain wordsIn men with prostate cancer given goserelin, no patient with a testosterone surge had clinical tumor flare symptoms.
Peptide
Goserelin
Outcome
Not applicableClinical tumor flare symptoms
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Studied dose
3.6 mg every 28 days or 10.8 mg every 84 days · 48 weeksAs given in this study (human).
Source sentences
Summary
No patient with a testosterone surge had clinical symptoms of a tumor flare reaction.
1 context sentence(design, population, supporting numbers)
Summary · context
Men with prostate cancer for whom hormonal therapy was indicated were randomized to open-label goserelin 3.6 mg every 28 days (n = 129) or 10.8 mg every 84 days (n = 118) for 48 weeks.
Report a problemFND-1559619306
07HumanNon-randomized trialEfficacy outcome
In men with prostate cancer, 77.4% receiving long-term goserelin maintained testosterone at 18.5 ng/dL or less.
In plain wordsIn men with prostate cancer, 77.4% receiving long-term goserelin maintained testosterone at 18.5 ng/dL or less.
Peptide
Goserelin
Outcome
Not applicableMaintenance of castrate testosterone
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.6 mg every 28 days or 10.8 mg every 84 days · 48 weeksAs given in this study (human).
Measurements
Patients maintaining castrate testosterone
77.4%
both goserelin doses
Source sentences
Summary
The testosterone levels were consistently maintained within the castrate range (18.5 ng/dL or less) in most (77.4%) patients receiving long-term 3.6 mg or 10.8 mg goserelin.
1 context sentence(design, population, supporting numbers)
Summary · context
Men with prostate cancer for whom hormonal therapy was indicated were randomized to open-label goserelin 3.6 mg every 28 days (n = 129) or 10.8 mg every 84 days (n = 118) for 48 weeks.
Report a problemFND-1559619307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT01366053

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

CMX Researchn = 125Mar 2011 to Jul 2015

Prostate Cancer

Trial page ClinicalTrials.govUpdated 22 Dec 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.